The latest Investing Matters Podcast with Jean Roche, Co-Manager of Schroder UK Mid Cap Investment Trust has just been released. Listen here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksDNL.L Regulatory News (DNL)

  • There is currently no data for DNL

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Results of Annual General Meeting

23 Nov 2016 11:30

RNS Number : 9559P
Diurnal Group PLC
23 November 2016
 

23 November 2016

 

 

Diurnal Group plc

("Diurnal" or the "Company")

 

Results of Annual General Meeting

 

 

Diurnal Group plc (AIM: DNL), the specialty pharmaceutical company targeting patient needs in chronic endocrine (hormonal) diseases, announces that all resolutions proposed to shareholders at its Annual General Meeting held today were duly passed. All resolutions were approved on a show of hands. The number of proxy votes received for each resolution is set out below.

 

 

Resolution

For (including discretionary votes)*

Against*

Withheld

Ordinary Resolutions (requires 50% majority)

1. To receive and adopt the Company's audited annual report and accounts for the year ended 30 June 2016.

39,347,209

100%

0

0%

0

2. To reappoint Peter Allen as a director.

39,347,209

100%

0

0%

0

3. To reappoint Ian Ardill as a director.

39,347,209

100%

0

0%

0

4. To reappoint John Goddard as a director.

39,347,209

100%

0

0%

0

5. To reappoint Alan Raymond as a director.

39,347,209

100%

0

0%

0

6. To reappoint Richard Ross as a director.

39,347,209

100%

0

0%

0

7. To reappoint Martin Whitaker as a director.

39,347,209

100%

0

0%

0

8. To reappoint Sam Williams as a director.

39,347,209

100%

0

0%

0

9. To receive and approve the directors' remuneration report contained within the annual report and accounts for the year ended 30 June 2016.

39,347,209

100%

0

0%

0

10. To reappoint KPMG LLP as auditors of the Company.

39,347,209

100%

0

0%

0

11. To authorise the directors to determine the remuneration of the auditors.

39,347,209

100%

0

0%

0

12. To authorise the directors to allot shares.

39,347,209

100%

0

0%

0

Special Resolutions (requires 75% majority)

13. To authorise the directors to disapply pre-emption rights.

39,347,209

100%

0

0%

0

14. To authorise the Company to make market purchases.

39,347,209

100%

0

0%

0

 

 

* A vote withheld is not a vote in law and is not counted in the calculation of the votes for or against a resolution; the percentage of votes cast therefore excludes withheld votes.

 

On 23 November 2016 there were 52,210,759 Diurnal Group plc ordinary shares in issue. Shareholders are entitled to one vote per share held.

 

The full text of each resolution passed at the Annual General Meeting held earlier today, is set out in the Notice of Annual General Meeting, included in the 2016 Annual Report, which is available on the Company's website www.diurnal.co.uk.

 

 

Please further information, please visit www.diurnal.co.uk or contact:

 

Diurnal Group plc

+44 (0)20 3727 1000

Martin Whitaker, CEO

Ian Ardill, CFO

Numis Securities Ltd

+44 (0)20 7260 1000

Nominated Adviser: Michael Meade, Freddie Barnfield, Paul Gillam

Corporate Broking: James Black

FTI Consulting

+ 44 (0)20 3727 1000

Simon Conway

Victoria Foster Mitchell

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
RAGBJBBTMBBTBPF
Date   Source Headline
17th Sep 202012:40 pmEQSHardman & Co Research: Diurnal Group (DNL): Closely watching the regulators
15th Sep 20207:00 amRNSResults for the year ended 30 June 2020
11th Sep 20207:00 amRNSShares and AJ Bell Investor Evening Webinar
3rd Sep 20205:33 pmRNSHoldings in Company
3rd Sep 20207:00 amRNSTwo further marketing and distribution agreements
27th Aug 20207:00 amRNSRichard Ross receives honour by Endocrine Society
20th Aug 20207:15 amEQSHardman & Co Research: Diurnal Group (DNL): Q&A with Dr Martin Hall
19th Aug 202010:00 amRNSNotice of Full Year Results
13th Aug 20202:06 pmRNSSecond Price Monitoring Extn
13th Aug 20202:00 pmRNSPrice Monitoring Extension
13th Aug 20207:15 amEQSHardman & Co Research: Diurnal Group (DNL): Flow of regulatory approvals
10th Aug 20209:14 amRNSHolding(s) in Company
10th Aug 20207:00 amRNSAlkindi approved in Australia
5th Aug 20207:00 amRNSAlkindi approved in Israel
30th Jul 20204:41 pmRNSSecond Price Monitoring Extn
30th Jul 20204:35 pmRNSPrice Monitoring Extension
30th Jul 20202:06 pmRNSSecond Price Monitoring Extn
30th Jul 20202:00 pmRNSPrice Monitoring Extension
30th Jul 202011:05 amRNSSecond Price Monitoring Extn
30th Jul 202011:00 amRNSPrice Monitoring Extension
30th Jul 20207:01 amRNSBusiness and trading update
30th Jul 20207:00 amRNSPositive DITEST Regulatory Meeting with US FDA
29th Jul 20204:41 pmRNSSecond Price Monitoring Extn
29th Jul 20204:36 pmRNSPrice Monitoring Extension
15th Jul 20201:04 pmRNSDirector Dealings
13th Jul 20201:29 pmRNSDirector Dealings and Issue of Equity
13th Jul 20201:28 pmRNSGrant of Deferred Share Awards
26th Jun 20202:29 pmRNSDirector Dealings
9th Jun 20207:00 amRNSChronocort Phase 3 data at ENDO Online 2020
29th May 20207:00 amRNSChange of Adviser
30th Apr 20209:05 amRNSSecond Price Monitoring Extn
30th Apr 20209:00 amRNSPrice Monitoring Extension
21st Apr 202010:05 amRNSDirector Dealings and Issue of Equity
16th Apr 20202:23 pmRNSDirector Dealings
15th Apr 20204:41 pmRNSSecond Price Monitoring Extn
15th Apr 20204:36 pmRNSPrice Monitoring Extension
15th Apr 20207:00 amRNSOperational Update
6th Apr 20209:21 amRNSDirector Dealings
1st Apr 20207:00 amRNSChronocort MAA Passes Validation Stage with EMA
30th Mar 20206:18 pmRNSHolding(s) in Company
30th Mar 20203:05 pmEQSHardman & Co Research: Diurnal (DNL): $52.5m US deal strengthens balance sheet further
27th Mar 20205:26 pmRNSHolding(s) in Company
27th Mar 20209:17 amRNSDirector Dealings
27th Mar 20207:00 amRNSUS Licencing Agreement with Eton Pharmaceuticals
26th Mar 20202:05 pmRNSSecond Price Monitoring Extn
26th Mar 20202:00 pmRNSPrice Monitoring Extension
25th Mar 20202:47 pmRNSResult of General Meeting and Issue of Equity
20th Mar 20204:48 pmRNSSecond Price Monitoring Extn
20th Mar 20204:39 pmRNSPrice Monitoring Extension
6th Mar 20204:55 pmRNSResult of Placing and Notice of General Meeting

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.